We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+11.94%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.64B
AUM Growth
-$192M
(-10%)
Cap. Flow
-$336M
Cap. Flow
% of AUM
-20.47%
Top 10 Holdings %
Top 10 Hldgs %
58.46%
Holding
59
New
16
Increased
10
Reduced
9
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$131M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$83.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$83M |
| 4 |
Eli Lilly
LLY
|
+$66M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$63.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$122M |
| 2 |
Quest Diagnostics
DGX
|
+$83.2M |
| 3 |
HOLX
Hologic
HOLX
|
+$79.3M |
| 4 |
Edwards Lifesciences
EW
|
+$67.8M |
| 5 |
AKRX
Akorn Inc
AKRX
|
+$59.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.82% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
26
DELISTED
Celgene Corp
CELG
| $15M | 0.92% |
+143,850
| New | +$15.6M |
|
|
27
Quest Diagnostics
DGX
$25.9B
| $13.4M | 0.82% |
158,780
-991,220
| -86% | -$83.2M |
|
|
AGN
28
DELISTED
Allergan plc
AGN
| $13.3M | 0.81% |
+57,550
| New | +$14.1M |
|
|
VAR
29
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
| $9.95M | 0.61% |
+114,038
| New | +$9.3M |
|
30
Medpace
MEDP
$16B
| $9.76M | 0.59% |
+326,685
| New | +$9.54M |
|
31
Arbutus Biopharma
ABUS
$845M
| $6.88M | 0.42% |
2,000,000
-258,300
| -11% | -$1.01M |
|
|
VXX
32
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
| $6.81M | 0.42% |
+50,000
| New | +$7.99M |
|
33
HCA Healthcare
HCA
$87B
| $6.79M | 0.41% |
89,740
-168,130
| -65% | -$12.9M |
|
|
SPNE
34
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $6.39M | 0.39% |
632,100
+9,000
| +1% | +$93K |
|
35
AMN Healthcare
AMN
$1.31B
| $4.22M | 0.26% |
+132,481
| New | +$5.03M |
|
36
Natera
NTRA
$38.1B
| $3.27M | 0.2% |
294,800
+4,200
| +1% | +$47.4K |
|
37
Align Technology
ALGN
$12.2B
| – | – |
-41,730
| Closed | -$3.36M |
|
38
BioMarin Pharmaceuticals
BMRN
$11.6B
| – | – |
-750,000
| Closed | -$58.4M |
|
39
Bristol-Myers Squibb
BMY
$133B
| – | – |
-211,940
| Closed | -$15.6M |
|
40
CVS Health
CVS
$134B
| – | – |
-237,830
| Closed | -$22.8M |
|
41
CALL
DexCom
DXCM
$32.4B
| – | – |
-800,000
| Closed | -$15.9M |
|
|
42
DexCom
DXCM
$32.4B
| – | – |
-1,584,120
| Closed | -$31.4M |
|
43
Gilead Sciences
GILD
$162B
| – | – |
-270,680
| Closed | -$22.6M |
|
44
Humana
HUM
$43.9B
| – | – |
-214,920
| Closed | -$38.7M |
|
45
Icon
ICLR
$12.8B
| – | – |
-475,000
| Closed | -$33.3M |
|
46
CALL
Merck
MRK
$323B
| – | – |
-1,048,000
| Closed | -$57.6M |
|
47
CALL
Neurocrine Biosciences
NBIX
$16.7B
| – | – |
-310,000
| Closed | -$14.1M |
|
|
48
Neurocrine Biosciences
NBIX
$16.7B
| – | – |
-450,000
| Closed | -$20.5M |
|
49
Revvity
RVTY
$12.6B
| – | – |
-582,500
| Closed | -$30.5M |
|
50
Thermo Fisher Scientific
TMO
$213B
| – | – |
-233,245
| Closed | -$34.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q3 2016 Portfolio in Review
As of Q3 2016, HealthCor Management held 59 positions worth $1.64B, down 10% from $1.83B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
HealthCor Management withdrew a net $336M in Q3 2016, closing 23 positions and reducing 9 holdings. Its most notable exit was Aetna Inc, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 78% a quarter earlier, followed by Financials.
Against the trend, HealthCor Management opened a new position in Cigna worth $130M.
- HealthCor Management's largest Q3 2016 buy was Cigna: 1,000,000 shares worth $130M.
- HealthCor Management added most to Merck in Q3 2016, an estimated $31.4M increase.
- HealthCor Management's biggest Q3 2016 reduction was Quest Diagnostics, cutting an estimated $83.2M.
- HealthCor Management fully exited Aetna Inc in Q3 2016, selling an estimated $122M.
- HealthCor Management's ten largest holdings make up 58% of its $1.64B portfolio in Q3 2016.
- HealthCor Management opened 16 new positions and closed 23 in Q3 2016.
- HealthCor Management's portfolio value fell 10% quarter-over-quarter to $1.64B.
Based on HealthCor Management's 13F filing for Q3 2016, filed 14 Nov 2016.